

Yelena Y Janjigian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4960905/publications.pdf>

Version: 2024-02-01

118
papers

16,071
citations

44042

48
h-index

20343

116
g-index

122
all docs

122
docs citations

122
times ranked

22430
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
3	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
4	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 27-40.	6.3	1,237
5	<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation. <i>Cancer Discovery</i> , 2012, 2, 922-933.	7.7	613
6	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	0.8	459
7	Gastric adenocarcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17036.	18.1	409
8	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	3.2	390
9	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant <i>EGFR</i> -Mutant Lung Cancer with and without T790M Mutations. <i>Cancer Discovery</i> , 2014, 4, 1036-1045.	7.7	348
10	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	13.7	335
11	Molecular Classification of Gastric Cancer: A New Paradigm. <i>Clinical Cancer Research</i> , 2011, 17, 2693-2701.	3.2	287
12	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
13	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
14	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known <i>BRCA</i> Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. <i>Oncologist</i> , 2011, 16, 1397-1402.	1.9	227
15	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
16	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3538-3546.	0.8	195
17	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1815-1822.	0.5	160
18	CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance. <i>Clinical Cancer Research</i> , 2014, 20, 3974-3988.	3.2	159

#	ARTICLE	IF	CITATIONS
19	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	13.7	156
20	Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. <i>Journal of Clinical Oncology</i> , 2015, 33, 3874-3879.	0.8	155
21	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 611-628.	1.9	146
22	<i>MET</i> Expression and Amplification in Patients with Localized Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1021-1027.	1.1	141
23	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	12.5	139
24	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	7.7	138
25	Clinical impact of tumour biology in the management of gastroesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 348-360.	12.5	132
26	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 569-575.	0.5	124
27	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	1.1	117
28	Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib. <i>Clinical Cancer Research</i> , 2011, 17, 2521-2527.	3.2	116
29	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
30	Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 670-675.	2.0	111
31	Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2010, 100, 443-447.	1.4	100
32	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	1.2	96
33	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 161-166.	2.8	96
34	Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with ¹⁸ F-FDG and ⁸⁹ Zr-Trastuzumab PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 936-943.	2.8	85
35	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. <i>Nature Communications</i> , 2018, 9, 5137.	5.8	78
36	Distinguishing Benign and Life-Threatening Pneumatosis Intestinalis in Patients With Cancer by CT Imaging Features. <i>American Journal of Roentgenology</i> , 2013, 200, 1042-1047.	1.0	75

#	ARTICLE	IF	CITATIONS
37	A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 623-631.	0.6	75
38	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4013-4013.	0.8	75
39	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
40	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. <i>Oncolmmunology</i> , 2017, 6, e1267891.	2.1	66
41	Morbidity after Total Gastrectomy: Analysis of 238 Patients. <i>Journal of the American College of Surgeons</i> , 2015, 220, 863-871e2.	0.2	65
42	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 836-843.e1.	0.4	62
43	Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1460-1465.	1.2	61
44	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. <i>Journal of Clinical Investigation</i> , 2016, 126, 681-694.	3.9	60
45	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. <i>ELife</i> , 2019, 8, .	2.8	59
46	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815.	0.8	58
47	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. <i>Clinical Cancer Research</i> , 2011, 17, 6322-6328.	3.2	57
48	Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center. <i>Annals of Surgery</i> , 2017, 266, 1006-1012.	2.1	56
49	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3926-3935.	3.2	55
50	A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 833-838.	1.1	52
51	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
52	The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 750-762.	0.6	45
53	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	3.3	44
54	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2710-2721.e3.	0.4	41

#	ARTICLE	IF	CITATIONS
55	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	7.7	40
56	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. <i>Future Oncology</i> , 2022, 18, 2465-2473.	1.1	40
57	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015, 10, e0134731.	1.1	38
58	Indications for Total Gastrectomy in <i>CDH1</i> Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. <i>JAMA Surgery</i> , 2020, 155, 1050.	2.2	34
59	⁸⁹ Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1386-1394.	2.8	33
60	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. <i>Cell Reports</i> , 2020, 31, 107840.	2.9	32
61	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2083-2090.	2.0	30
62	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. <i>Annals of Surgical Oncology</i> , 2014, 21, 1130-1137.	0.7	29
63	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1569-1578.	2.8	27
64	Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 864-871.	0.7	26
65	Esophageal Reinforcement with an Extracellular Scaffold During Total Gastrectomy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1252-1257.	0.7	25
66	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 475-477.	0.8	25
67	Genomic Dysregulation in gastric tumors. <i>Journal of Surgical Oncology</i> , 2013, 107, 237-242.	0.8	24
68	Risk factors for recurrence in T1â€2NO gastric cancer in the United States and China. <i>Journal of Surgical Oncology</i> , 2016, 113, 745-749.	0.8	22
69	Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. <i>Annals of Thoracic Surgery</i> , 2020, 109, 329-336.	0.7	20
70	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2027-2033.	0.7	19
71	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 237-247.	1.8	18
72	Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?. <i>Journal of Clinical Oncology</i> , 2016, 34, 401-403.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2021, 28, 3532-3544.	0.7	17
74	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. <i>Lung Cancer</i> , 2017, 113, 51-58.	0.9	16
75	Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. <i>Cancer Cell</i> , 2021, 39, 738-742.	7.7	16
76	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1658-1665.	2.9	15
77	Positron-Emission Tomography Scan-â€œDirected Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. <i>Journal of Thoracic Oncology</i> , 2019, 14, 540-546.	0.5	15
78	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
79	Talking to patients about biosimilars. <i>Future Oncology</i> , 2018, 14, 2403-2414.	1.1	14
80	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 4829-4838.	0.7	14
81	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 430-438.	0.3	14
82	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-â€œPhenotype Features-â€œAn Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , 2018, 17, e315-e321.	1.0	13
83	Unique Considerations for Females Undergoing Esophagectomy. <i>Annals of Surgery</i> , 2020, 272, 113-117.	2.1	13
84	A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 312-317.	2.1	13
85	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 506-514.	0.6	12
86	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 355-362.	2.7	11
87	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3811-3817.	3.2	10
88	Regorafenib in Combination with First-â€œLine Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	1.9	10
89	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. <i>Nature Communications</i> , 2022, 13, 2526.	5.8	10
90	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 898-904.	2.1	9

#	ARTICLE	IF	CITATIONS
91	Checkpoint blockade in esophagogastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 77-85.	0.8	9
92	Oligometastases After Curative Esophagectomy Are Not One Size Fits All. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1775-1781.	0.7	9
93	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor- Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
94	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021, 27, 3491-3498.	3.2	8
95	Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2023, 277, e538-e544.	2.1	7
96	Molecularly targeted therapies in advanced gastric cancer. <i>Minerva Gastroenterologica E Dietologica</i> , 2011, 57, 75-88.	2.2	7
97	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 126-130.	0.6	6
98	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 828-837.	0.6	6
99	Targeting EGFR in Esophagogastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 553876.	1.3	6
100	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. <i>Annals of Surgery</i> , 2020, , .	2.1	5
101	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. <i>JCO Precision Oncology</i> , 2022, 6, e2100242.	1.5	5
102	Application of positron emission tomography imaging to personalize esophagogastric cancer care. <i>Cancer</i> , 2019, 125, 1214-1217.	2.0	4
103	Postoperative ctDNA monitoring: a canary in a coalmine. <i>Annals of Oncology</i> , 2021, 32, 431-433.	0.6	4
104	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. <i>Future Oncology</i> , 2016, 12, 839-854.	1.1	3
105	Abstract CT228: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer. <i>Cancer Research</i> , 2014, 74, CT228-CT228.	0.4	3
106	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	3.0	3
107	Comment on "Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer". <i>Annals of Surgery</i> , 2019, 270, e39-e40.	2.1	2
108	A nutritional management algorithm in older patients with locally advanced esophageal cancer. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	2

#	ARTICLE	IF	CITATIONS
109	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World Journal of Oncology, 2021, 12, 183-194.	0.6	2
110	Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?. Nature Clinical Practice Oncology, 2008, 5, 10-11.	4.3	1
111	Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 313-324.	0.6	1
112	A case of advanced gastric cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 59-63.	0.8	1
113	Phase I/IIb study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	1.1	1
114	Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer, 2022, 128, 1894-1899.	2.0	1
115	Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3123-3132.	0.6	1
116	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	0.7	0
117	Role of HER2 in Gastric Cancers. , 2015, , 77-89.		0
118	Stomach: The Standard of Care ± HER2. , 2021, , 75-88.		0